

Highlights of This Issue 1383

SPOTLIGHT ON CLINICAL RESPONSE

- 1385 | **Early FDG/PET Scanning as a Pharmacodynamic Marker of Anti-EGFR Antibody Activity in Colorectal Cancer**
Geoffrey W. Krystal, Erin Alesi, and James L. Tatum

THERAPEUTIC DISCOVERY

- 1389 | **Inducible Silencing of Protein Kinase D3 Inhibits Secretion of Tumor-Promoting Factors in Prostate Cancer**
Courtney R. LaValle, Liyong Zhang, Shuping Xu, Julie L. Eiseman, and Q. Jane Wang
- 1400 | **Human Monoclonal Antibodies Targeting Nonoverlapping Epitopes on Insulin-like Growth Factor II as a Novel Type of Candidate Cancer Therapeutics**
Weizao Chen, Yang Feng, Qi Zhao, Zhongyu Zhu, and Dimitar S. Dimitrov
- 1411 | **ErbB3 Inhibitory Surrobbodies Inhibit Tumor Cell Proliferation *In Vitro* and *In Vivo***
Pamela K. Foreman, Medini Gore, Philip A. Kobel, Li Xu, Helena Yee, Charles Hannum, Hoangdung Ho, Sandra M. Wang, Hieu V. Tran, Michael Horowitz, Lawrence Horowitz, and Ramesh R. Bhatt
- 1421 | **Betulinic Acid Targets YY1 and ErbB2 through Cannabinoid Receptor-Dependent Disruption of MicroRNA-27a:ZBTB10 in Breast Cancer**
Xinyi Liu, Indira Jutooru, Ping Lei, KyoungHyun Kim, Syng-ook Lee, Lisa K. Brents, Paul L. Prather, and Stephen Safe

- 1432 | **Adenosine A2A and Beta-2 Adrenergic Receptor Agonists: Novel Selective and Synergistic Multiple Myeloma Targets Discovered through Systematic Combination Screening**
Richard J. Rickles, Winnie F. Tam, Thomas P. Giordano III, Laura T. Pierce, Melissa Farwell, Douglas W. McMillin, Antoaneta Necheva, David Crowe, Mei Chen, William Avery, Vikram Kansra, Steffan T. Nawrocki, Jennifer S. Carew, Francis J. Giles, Constantine S. Mitsiades, Alexis A. Borisy, Kenneth C. Anderson, and Margaret S. Lee
- 1443 | **Inhibition of ATR-Dependent Signaling by Protoapigenone and Its Derivative Sensitizes Cancer Cells to Interstrand Cross-link-Generating Agents *In Vitro* and *In Vivo***
Hui-Chun Wang, Alan Yueh-Luen Lee, Wen-Cheng Chou, Chin-Chung Wu, Chao-Neng Tseng, Kevin Yen-Ting Liu, Wen-Lien Lin, Fang-Rong Chang, Da-Wei Chuang, Attila Hunyadi, and Yang-Chang Wu
- 1454 | **microRNA-9 Targets Matrix Metalloproteinase 14 to Inhibit Invasion, Metastasis, and Angiogenesis of Neuroblastoma Cells**
Huanyu Zhang, Meng Qi, Shiwang Li, Teng Qi, Hong Mei, Kai Huang, Liduan Zheng, and Qiangsong Tong
- 1467 | **Impact of Intrinsic Affinity on Functional Binding and Biological Activity of EGFR Antibodies**
Yu Zhou, Anne-Laure Goenaga, Brian D. Harms, Hao Zou, Jianlong Lou, Fraser Conrad, Gregory P. Adams, Birgit Schoeberl, Ulrik B. Nielsen, and James D. Marks
- 1477 | **Engineering and Therapeutic Application of Single-Chain Bivalent TGF- β Family Traps**
John C. Zwaagstra, Traian Sulea, Jason Baardsnes, Anne E.G. Lenferink, Cathy Collins, Christiane Cantin, Béatrice Paul-Roc, Suzanne Grothe, Sazzad Hossain, Louis-Philippe Richer, Denis L'Abbé, Roseanne Tom, Brian Cass, Yves Durocher, and Maureen D. O'Connor-McCourt

PRECLINICAL DEVELOPMENT

- 1488 **Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells**
C. Elizabeth Caldon, C. Marcelo Sergio, Jian Kang, Anita Muthukaruppan, Marijke N. Boersma, Andrew Stone, Jane Barraclough, Christine S. Lee, Michael A. Black, Lance D. Miller, Julia M. Gee, Rob I. Nicholson, Robert L. Sutherland, Cristin G. Print, and Elizabeth A. Musgrove
- 1500 **Characterization of an Oxaliplatin Sensitivity Predictor in a Preclinical Murine Model of Colorectal Cancer**
Mickey K. Kim, Takuya Osada, William T. Barry, Xiao Yi Yang, Jennifer A. Freedman, Katherine A. Tsamis, Michael Datto, Bryan M. Clary, Timothy Clay, Michael A. Morse, Philip G. Febbo, H. Kim Lysterly, and David S. Hsu
- 1510 **Modulation of Akt/mTOR Signaling Overcomes Sunitinib Resistance in Renal and Prostate Cancer Cells**
Peter B. Makhov, Konstantin Golovine, Alexander Kutikov, Ervin Teper, Daniel J. Canter, Jay Simhan, Robert G. Uzzo, and Vladimir M. Kolenko
- 1518 **XIAP Inhibition and Generation of Reactive Oxygen Species Enhances TRAIL Sensitivity in Inflammatory Breast Cancer Cells**
Jennifer L. Allensworth, Katherine M. Aird, Amy J. Aldrich, Ines Batinic-Haberle, and Gayathri R. Devi
- 1528 **Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas**
Giuliana Cavalloni, Caterina Peraldo-Neia, Ivana Sarotto, Loretta Gammaitoni, Giorgia Migliardi, Marco Soster, Serena Marchiò, Massimo Aglietta, and Francesco Leone
- 1539 **Effect of a Low-Fat Diet Combined with IGF-1 Receptor Blockade on 22Rv1 Prostate Cancer Xenografts**
Ramdev Konijeti, Satomi Koyama, Ashley Gray, R. James Barnard, Jonathan W. Said, Brandon Castor, David Elashoff, Junxiang Wan, Pedro J. Beltran, Frank J. Calzone, Pinchas Cohen, Colette Galet, and William J. Aronson

- 1547 **Thermal Targeting of an Acid-Sensitive Doxorubicin Conjugate of Elastin-like Polypeptide Enhances the Therapeutic Efficacy Compared with the Parent Compound *In Vivo***
Shama Moktan, Eddie Perkins, Felix Kratz, and Drazen Raucher
- 1557 **Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) in Gastric Cancer Positive for MET Amplification**
Wataru Okamoto, Isamu Okamoto, Tokuzo Arao, Kiyoko Kuwata, Erina Hatashita, Haruka Yamaguchi, Kazuko Sakai, Kazuyoshi Yanagihara, Kazuto Nishio, and Kazuhiko Nakagawa
- 1565 **Preclinical Analysis of the γ -Secretase Inhibitor PF-03084014 in Combination with Glucocorticoids in T-cell Acute Lymphoblastic Leukemia**
Jeremy B. Samon, Mireia Castillo-Martin, Michael Hadler, Alberto Ambesi-Impiobato, Elisabeth Paietta, Janis Racevskis, Peter H. Wiernik, Jacob M. Rowe, John Jakubczak, Sophia Randolph, Carlos Cordon-Cardo, and Adolfo A. Ferrando
- 1576 **Targeting the Insulin Growth Factor and the Vascular Endothelial Growth Factor Pathways in Ovarian Cancer**
Minghai Shao, Stacy Hollar, Daphne Chambliss, Jordan Schmitt, Robert Emerson, Bhadrani Chelladurai, Susan Perkins, Mircea Ivan, and Daniela Matei
- 1587 **Smoothened Antagonists Reverse Taxane Resistance in Ovarian Cancer**
Adam D. Steg, Ashwini A. Katre, Kerri S. Bevis, Angela Ziebarth, Zachary C. Dobbin, Monjri M. Shah, Ronald D. Alvarez, and Charles N. Landen
- 1598 **CDK-4 Inhibitor P276 Sensitizes Pancreatic Cancer Cells to Gemcitabine-Induced Apoptosis**
Dharmalingam Subramaniam, Giridharan Periyasamy, Sivapriya Ponnuram, Debarshi Chakrabarti, Aravind Sugumar, Muralidhara Padigar, Scott J. Weir, Arun Balakrishnan, Somesh Sharma, and Shrikant Anant

MOLECULAR MEDICINE IN PRACTICE

1609

The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer

Craig P. Carden, Adam Stewart, Parames Thavas, Emma Kipps, Lorna Pope, Mateus Crespo, Susana Miranda, Gerhardt Attard, Michelle D. Garrett, Paul A. Clarke, Paul Workman, Johann S. de Bono, Martin Gore, Stan B Kaye, and Udai Banerji

ABOUT THE COVER

Deregulation of TGF- β superfamily signaling is a causative factor in many diseases. Bivalent single-chain traps that neutralize TGF- β family ligands (green and orange) were rationally designed using native intrinsically disordered regions as linkers (black) between two cognate receptor binding domains (magenta). TGF- β traps designed by this innovative strategy can achieve similar or better *in vitro* potency and *in vivo* tumor growth inhibition compared to a neutralizing antibody, indicating their promising therapeutic potential. For details, see article by Zwaagstra and colleagues on page 1477.

